Hyperion Therapeutics Announces First Patient Enrolled in Pivotal Trial in Patients With Urea Cycle Disorders
10/27/2009 9:52:49 AM
More...
|
Hyperion Therapeutics to Present at UBS 2009 Global Life Sciences Conference
9/18/2009 10:28:25 AM
More...
|
Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Hepatic Encephalopathy
9/17/2009 8:52:10 AM
More...
|
Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Hepatic Encephalopathy
9/17/2009 8:41:00 AM
More...
|
Company Profile for Hyperion Therapeutics
7/17/2009 9:37:38 AM
More...
|
Hyperion Therapeutics Receives Special Protocol Assessment Approval From FDA for Pivotal Phase III Trial in Urea Cycle Disorders
7/7/2009 8:59:12 AM
More...
|
Hyperion Therapeutics Raises $60 Million Series C
6/30/2009 7:15:28 AM
More...
|
Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
6/2/2009 11:35:57 AM
More...
|
Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
5/5/2009 11:59:12 AM
More...
|
Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
3/30/2009 8:15:09 AM
More...
|
|